Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 16, 2026.

The epidemiology of venous thromboembolism

John A. Heit, Frederick A. Spencer, Richard H. White

Journal of Thrombosis and Thrombolysis · 2016 · Review

doi:10.1007/s11239-015-1311-6

Abstract

Venous thromboembolism (VTE) is categorized by the U.S. Surgeon General as a major public health problem. VTE is relatively common and associated with reduced survival and substantial health-care costs, and recurs frequently. VTE is a complex (multifactorial) disease, involving interactions between acquired or inherited predispositions to thrombosis and VTE risk factors, including increasing patient age and obesity, hospitalization for surgery or acute illness, nursing-home confinement, active cancer, trauma or fracture, immobility or leg paresis, superficial vein thrombosis, and, in women, pregnancy and puerperium, oral contraception, and hormone therapy. Although independent VTE risk factors and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence of VTE seems to be relatively constant, or even increasing.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 16, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Thrombosis can affect virtually any venous circulation. This chapter focuses on the epidemiology of venous thromboembolism (VTE), including deep vein thrombosis (DVT) of the leg or pelvis, and its complication, pulmonary embolism (PE). Thrombosis affecting the superficial leg (e.g. saphenous) veins and other venous circulations (e.g. arm, cerebral, mesenteric, renal, hepatic, portal veins) is beyond the scope of this chapter. VTE is a complex (multifactorial) disease, involving interaction between acquired or inherited predispositions to thrombosis (i.e. thrombophilia) and environmental exposures (i.e. clinical risk factors). Moreover, the type of VTE event (PE vs. DVT) may also be partly heritable. Most studies of VTE epidemiology addressed populations of predominantly European origin, and the data discussed in this chapter mainly relate to these populations. Where available, data from populations originating from other continents are presented.

Methods

This chapter focuses on population-based studies and addresses nine questions regarding the epidemiology of VTE (Table 1). Questions were developed by consensus from the authors. The literature addressing the above questions was reviewed by searching electronic databases (PubMed, Medline), including the references of all identified papers and the author’s personal libraries. Since this review is informational only and does not address diagnosis, treatment or management of VTE, there are no associated guidance statements. The post thrombotic syndrome and the epidemiology of inherited and acquired thrombophilia are reviewed in Chapters 9 and 10, respectively.

Questions

What is the incidence of VTE, PE with or without (±) DVT and leg DVT alone, both overall, and by age, sex and race, and by idiopathic versus secondary VTE?

What is the incidence of VTE, PE with or without (±) DVT and leg DVT alone, both overall, and by age, sex and race, and by idiopathic versus secondary VTE?

The estimated average annual incidence rate of overall VTE among persons of European ancestry ranges from 104 to 183 per 100,000 person-years; overall VTE incidence is similar to that of stroke. Overall VTE incidence may be higher in African-Americans and lower in Asians, and Asian- and Native-Americans, and may differ among African-Americans by United States region. Reported incidence rates for PE ± DVT, and for leg DVT alone, range from 29 to 78, and 45 to 117, per 100,000 person-years, respectively.

VTE is predominantly a disease of older age; VTE is rare prior to late adolescence. Incidence rates increase markedly with age for both men and women (Fig. 1) and for both DVT and PE (Fig. 2). The overall age-adjusted incidence rate is higher for men (130 per 100,000) then women (110 per 100,000; male:female sex ratio is 1.2:1). Incidence rates are somewhat higher in women during childbearing years, while incidence rates after age 45 years are generally higher in men. PE accounts for an increasing proportion of VTE with increasing age for both sexes. The percentage of incident VTE events that are idiopathic ranges from 25 to 40 %. In one study, 19 % of events among Asian/Pacific Islanders were idiopathic.

What are the trends in incidence over time of overall VTE, leg DVT alone and PE ± DVT, and of idiopathic versus secondary VTE? How are these trends affected by changes in diagnostic test utilization, imaging resolution and autopsy rates over time?

What are the trends in incidence over time of overall VTE, leg DVT alone and PE ± DVT, and of idiopathic versus secondary VTE? How are these trends affected by changes in diagnostic test utilization, imaging resolution and autopsy rates over time?

Data on trends in VTE incidence are limited; overall VTE incidence rates as well as incidence rates for PE ± DVT and DVT alone either remained relatively constant or increased for the period, 1981-2000, with a significant increase in the overall VTE incidence rate from 2001 to 2009, mostly due to an increasing incidence of PE ± DVT (Fig. 3). The incidence rates of incident cancer-associated VTE, secondary non cancer-associated VTE and idiopathic VTE, 1999–2009, appear to be relatively constant. The observed increase in overall VTE and PE ± DVT incidence rates over the most recent time period may, in part, reflect increased utilization of objective imaging and improved image resolution, particularly computed tomography, pulmonary angiography, and magnetic resonance imaging.

What is the cumulative incidence of VTE recurrence, both overall and by leg DVT alone vs. PE ± DVT?

What is the cumulative incidence of VTE recurrence, both overall and by leg DVT alone vs. PE ± DVT?

VTE recurs frequently; about 30 % of patients develop recurrence within the next 10 years (Fig. 4); reported incidence rates of recurrent overall VTE, PE ± DVT and DVT alone range from 19 to 39, 4-13, and 15 to 29 per 100,000 person-years, respectively. The hazard of recurrence varies with the time since the incident event and is highest within the first 6–12 months but never falls to zero. While secondary prophylaxis is effective in preventing recurrence, the duration of acute treatment does not affect the rate of recurrence after three months of adequate anticoagulation has been completed. These data suggest that VTE is a chronic disease with episodic recurrence.

What baseline and time-dependent characteristics are independent predictors of VTE recurrence after adjustment for primary treatment and secondary prophylaxis? Within the major predictors of VTE recurrence, can the individual patient be further stratified into high and low risk? How well do available VTE recurrence risk-prediction scores operate in predicting recurrence?

What baseline and time-dependent characteristics are independent predictors of VTE recurrence after adjustment for primary treatment and secondary prophylaxis? Within the major predictors of VTE recurrence, can the individual patient be further stratified into high and low risk? How well do available VTE recurrence risk-prediction scores operate in predicting recurrence?

Independent predictors of recurrence include increasing patient age (per 10 years and body mass index (per 10 kg/m2) male sex, active cancer, and neurologic disease with leg paresis. Additional predictors of recurrence include idiopathic VTE, a lupus anticoagulant or antiphospholipid antibody, antithrombin, protein C or protein S deficiency, hyperhomocysteinemia, a persistently increased plasma D-dimer among patients with idiopathic VTE, and possibly residual vein thrombosis. Among active cancer patients, VTE recurrence risk can be further stratified by cancer site (pancreatic, brain, lung and ovarian cancer, myeloproliferative or myelodysplastic disorders), stage IV cancer, cancer stage progression and leg paresis.

Of equal importance, several risk factors present at the time of the incident VTE event are associated with either a reduced risk of recurrence or are not predictive of recurrence. For women, pregnancy or the postpartum state, oral contraceptive use, hormone therapy, and gynecologic surgery are associated with a reduced risk of recurrence. Recent surgery and trauma/fracture either have no effect or predict a reduced risk of recurrence. Additional characteristics having no significant effect on recurrence risk include recent immobilization, tamoxifen therapy, and failed prophylaxis. For these patients, and for patients with isolated calf vein thrombosis, a shorter duration (i.e., 6 weeks) of acute therapy likely is adequate. While data on the type of incident event type (DVT alone vs. PE ± DVT) as a predictor of recurrence are conflicting, patients with a recurrent event are significantly more likely to have the same type of VTE event as the incident event type.

Several VTE recurrence prediction scores have been derived for stratifying recurrence risk among patients with incident idiopathic or cancer-associated VTE. In the “Men continue and HERDOO2″ score, there were no predictors of a reduced risk of recurrence among men with incident idiopathic VTE. In contrast, women with idiopathic VTE who had ≤1 of the following risk factors had a significantly lower risk of VTE recurrence: (1) older age (≥ 65 years), (2) obesity (BMI ≥ 30 kg/m2), (3) an increased D-dimer prior to stopping warfarin therapy and (4) signs of post thrombotic syndrome. In the Vienna prediction model, male sex, incident VTE site (PE and proximal DVT vs. isolated calf DVT) and increasing D-dimer level were predictors of recurrence after idiopathic incident VTE. In the DASH prediction score, a persistently increased D-dimer after stopping anticoagulation therapy, age <50 years, male sex and VTE unrelated to hormonal therapy (in women) predicted an increased risk of recurrence after an “idiopathic” incident VTE. Thus, the only inconsistent risk factor in these models is the effect of patient age, with older and younger age being associated with a higher recurrence risk among women in the HERDOO2 model and among men and women in the DASH model, respectively, while patient age was not a predictor of recurrence in the Vienna model. Depending on the model, patients with a low score had 1.6–4.4 % per year recurrence rates. Assuming these recurrence rates are acceptable, about 50 % of patients with idiopathic incident VTE and a low prediction score could avoid secondary prophylaxis. Among active cancer patients with VTE, patient sex, cancer site (lung, breast), cancer stage and prior VTE were predictors of VTE recurrence while on anticoagulation therapy.

What are the attack rates (i.e. incident and recurrent VTE) of VTE, both overall and by hospitalization-related versus community-acquired VTE? What is the total number of VTE events (incident and recurrent) per year in the USA?

What are the attack rates (i.e. incident and recurrent VTE) of VTE, both overall and by hospitalization-related versus community-acquired VTE? What is the total number of VTE events (incident and recurrent) per year in the USA?

Estimated overall VTE attack rates range from 142 to over 300 per 100,000 person-years; estimated attack rates for PE ± DVT and DVT alone range from 51 to 75 and 91 to 255 per 100,000, respectively. Overall VTE attack rates related to current or recent hospitalization are much higher compared to rates among persons residing in the community (330 vs. 8 per 100,000, respectively).

There are few data on the total number of VTE events (incident and recurrent) occurring in the USA per year, and available estimates vary widely. Using age- and sex-specific incidence rates for the five-year time period, 1991–95, projected to the 2000 United States white population, at least 260,000 first-lifetime cases of VTE occur among whites in the United States annually. If incidence rates among African-Americans are similar, then 27,000 additional incident cases occur among African-Americans in the United States annually. In an incidence-based modeling study that included both hospital- and community-acquired, incident and recurrent VTE events, an estimated 600,000 non-fatal VTE events (370,000 DVT and 270,000 PE) occurred in the USA in 2005; of the total, approximately two-thirds were related to current or recent hospitalization. Using 2007-2009 National Hospital Discharge Survey discharge diagnosis codes, an estimated average of about 548,000 hospitalizations with VTE occurred each year among USA residents aged ≥18 years, of which 349,000 were DVT and 278,000 were PE.

What are the VTE-attributable costs?

What are the VTE-attributable costs?

In population-based studies, the adjusted mean predicted costs were 2.5-fold higher for patients with VTE related to current or recent hospitalization for acute medical illness ($62,838) compared to hospitalized controls matched on active cancer status ($24,464; p < 0.001) from the VTE event date (or index date for controls) to 5 years post index; cost differences between cases and controls were greatest within the first 3 months (mean difference = $16,897). Similarly, the adjusted mean predicted costs were 1.5-fold higher for patients with VTE related to current or recent hospitalization for major surgery ($55,956) compared to hospitalized controls matched to cases on type of surgery and active cancer status ($32,718; p < 0.001) from the VTE event date (or index date for controls) to 5 years post index. Cost differences between cases and controls were also greatest within the first 3 months after index (mean difference = $12,381). Costs were significantly higher for cases than controls (mean difference = $10,797) from 3 months to up to 5 years post-index and together accounted for about half of the overall cost difference. Finally, the adjusted mean predicted costs were over 2-fold higher for patients with VTE related to active cancer ($52,422) compared to active cancer controls matched on the duration of active cancer ($23,951; p < 0.001) from the VTE event date (or index date for controls) to 5 years post index. Cost differences between cases and controls were greatest within the first 3 months (mean difference = $16,488) but remained significantly higher for up to 4 years after index.

What is the survival after VTE overall, and after leg DVT alone vs. PE ± DVT. What are the independent predictors of survival? What are the trends in survival over time after PE ± DVT?

What is the survival after VTE overall, and after leg DVT alone vs. PE ± DVT. What are the independent predictors of survival? What are the trends in survival over time after PE ± DVT?

Overall, survival after VTE is worse than expected, and survival after PE is much worse than after DVT alone (Table 2). The risk of early death among PE patients is 18-fold higher compared with patients with DVT alone. Pulmonary embolism is an independent predictor of reduced survival for up to 3 months after onset. After 3 months, observed survival after PE is similar to expected survival. For almost one-quarter of PE patients, the initial clinical presentation is sudden death. Independent predictors of reduced early survival after VTE include increasing age, male sex, lower body mass index, confinement to a hospital or nursing home at VTE onset, congestive heart failure, chronic lung disease, serious neurologic disease, and active cancer. Additional clinical predictors of poor early survival after PE include syncope and arterial hypotension. Evidence of right heart failure based on clinical examination, plasma markers (e.g. cardiac troponin T, brain natriuretic peptide) or echocardiography predicts poor survival among normotensive PE patients. Survival over time may be improving for those PE patients living sufficiently long to be diagnosed and treated.

What are the independent risk factors for VTE? How well do incident VTE risk prediction scores operate in predicting incident VTE for the individual?

What are the independent risk factors for VTE? How well do incident VTE risk prediction scores operate in predicting incident VTE for the individual?

Independent risk factors for VTE include increasing patient age and body mass index, major surgery, hospitalization for acute medical illness, nursing home confinement, trauma/fracture, active cancer with or without concurrent chemotherapy, central vein catheterization or transvenous pacemaker, prior superficial vein thrombosis, varicose veins, neurologic disease with leg paresis, urinary tract infection, an increased baseline plasma fibrin D-dimer and family history of venous thromboembolism; patients with chronic liver disease have a reduced risk (Table 3). Compared to residents in the community, hospitalized residents have over a 100-fold increased incidence of VTE. Hospitalization and nursing home residence together account for almost 60 % of incident VTE events occurring in the community. Of note, hospitalization for medical illness and hospitalization for surgery account for almost equal proportions of VTE (22 and 24 %, respectively). Nursing home residence independently accounts for over one-tenth of all VTE disease in the community.

VTE risk among surgery patients can be further stratified based on patient age, type of surgery, smoking and the presence of active cancer. The incidence of postoperative VTE is increased for surgery patients ≥65 years of age. High VTE-risk surgical procedures include neurosurgery, major orthopedic surgery of the leg, thoracic, abdominal or pelvic surgery for cancer, renal transplantation, and cardiovascular surgery. Obesity, and poor American Society of Anesthesiology physical status are risk factors for VTE after total hip arthroplasty.

VTE risk among patients hospitalized for acute medical illness may be further stratified based on increasing patient age, obesity, previous VTE, thrombophilia, cancer, recent trauma or surgery, tachycardia, acute myocardial infarction or stroke, leg paresis, congestive heart failure, prolonged immobilization (bed rest), acute infection or rheumatologic disorder, hormone therapy, central venous catheter, admission to an intensive or coronary care unit, white blood cell count and platelet count.

While risk assessment models for predicting VTE among hospitalized non-surgical patients have been derived, the number, predictor types and strength of association with VTE are highly variable and lack generalizability and adequate validation.

Active cancer accounts for almost 20 % of all incident VTE occurring in the community. The risk appears to be higher for patients with cancer of the brain, pancreas, ovary, colon, stomach, lung, kidney and bone, and in patients with distant metastases. Cancer patients receiving immunosuppressive or cytotoxic chemotherapy are at even higher risk for VTE, including therapy with L-aspariginase, thalidomide or lenalidomide, or tamoxifen. Routine screening for occult cancer is controversial and likely not warranted. However, if clinical features suggest a possible occult cancer (i.e. idiopathic VTE, especially among patients with abdominal vein or bilateral leg vein thrombosis or in whom VTE recurs) then the only imaging study shown to be useful is a CT scan of the abdomen and pelvis. Among cancer patients, the risk of chemotherapy-associated VTE is increased in patients with pancreatic or gastric cancer, platelet count ≥350 × 109/L, hemoglobin <100 g/L or use of red cell growth factors, leukocyte count ≥11 × 109/L, or body mass index ≥35 kg/m2; biomarkers (plasma soluble P-selectin and D-dimer) add further predictive value.

A central venous catheter or transvenous pacemaker accounts for 9 % of all incident VTE occurring in the community. Central venous access via femoral vein catheters is associated with a higher incidence of VTE compared to subclavian vein catheterization. Prior superficial vein thrombosis is an independent risk factor for subsequent DVT or PE remote from the episode of superficial thrombophlebitis. The risk of DVT imparted by varicose veins is uncertain and appears to vary by patient age. Long haul (>4–6 h) air travel is associated with a slightly increased risk for VTE (~1 per 4656 flights) that is preventable with elastic stockings. HMG-Coenzyme A reductase inhibitor (statin) therapy may provide a 20–50 % risk reduction for VTE. Hypertriglyceridemia doubles the risk of VTE in postmenopausal women. However, the risk associated with atherosclerosis, or other risk factors for atherosclerosis, remains uncertain. Diabetes mellitus, myocardial infarction, current or past tobacco smoking, high-density lipoprotein cholesterol, lipoprotein (a), chronic obstructive pulmonary disease, and renal failure are not independent risk factors for VTE. The risk associated with congestive heart failure, independent of hospitalization, is low.

Among women, additional risk factors for VTE include oral contraceptive use, hormone therapy, pregnancy and the postpartum period, and therapy with the selective estrogen receptor modulator, raloxifene. First and third generation oral contraceptives convey higher risk than second generation oral contraceptives. Injectable depot-medroxyprogesterone acetate for contraception is associated with a three-fold increased risk for venous thromboembolism, while a levonorgestrel intrauterine device imparts no risk. Hormone therapy is associated with a 2- to fourfold increased risk of VTE, but the risk may vary by type of estrogen and there may be no risk with transdermal estrogen therapy. The overall incidence of pregnancy-associated VTE is about 200 per 100,000 woman-years; compared to non-pregnant women of childbearing age, the relative risk is increased about fourfold. The risk during the postpartum period is about fivefold higher than the risk during pregnancy. Prior superficial vein thrombosis is an independent risk factor for VTE during pregnancy or postpartum.

Other conditions associated with VTE include autoimmune disorders, Behcet’s syndrome, celiac disease, heparin-induced thrombocytopenia, homocystinuria and hyperhomocysteinemia, hyperthyroidism, immune thrombocytopenia (ITP), infection, inflammatory bowel disease, intravascular coagulation and fibrinolysis/disseminated intravascular coagulation (ICF/DIC), myeloproliferative disorders (especially polycythemia rubra vera and essential thrombocythemia), chronic kidney disease with severely reduced glomerular filtration rate, nephrotic syndrome, paroxysmal nocturnal hemoglobinuria, rheumatoid arthritis, obstructive sleep apnea, thromboangiitis obliterans (Buerger’s disease), thrombotic thrombocytopenic purpura, sickle cell disease, systemic lupus erythematosus, and granulomatosis with polyangiitis (Wegener’s).

References 202

  1. 1.

    Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet. 2000;67:1452-1459.

    Not in our library10.1086/316903

  2. 2.

    Ariens RA, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet. 2002;359:667-671.

    Not in our library10.1016/s0140-6736(02)07813-3

  3. 3.

    Larsen TB, Sorensen HT, Skytthe A, Johnsen SP, Vaupel JW, Christensen K. Major genetic susceptibility for venous thromboembolism in men: a study of Danish twins. Epidemiology. 2003;14:328-332.

    Not in our library

  4. 4.

    Heit JA, Phelps MA, Ward SA, Slusser JP, Petterson TM, De Andrade M. Familial segregation of venous thromboembolism. J Thromb Haemost. 2004;2:731-736.

    Not in our library10.1111/j.1538-7933.2004.00660.x

  5. 5.

    Zoller B, Ohlsson H, Sundquist J, Sundquist K. Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. Thromb Haemost. 2013;109:458-463.

    Not in our library10.1160/th12-10-0743

  6. 6.

    Zoller B, Li X, Sundquist J, Sundquist K. A nationwide family study of pulmonary embolism: identification of high risk families with increased risk of hospitalized and fatal pulmonary embolism. Thromb Res. 2012;130:178-182.

    Not in our library10.1016/j.thromres.2012.02.002

  7. 7.

    Zoller B, Li X, Sundquist J, Sundquist K. Shared familial aggregation of susceptibility to different manifestations of venous thromboembolism: a nationwide family study in Sweden. Br J Haematol. 2012;157:146-148.

    Not in our library10.1111/j.1365-2141.2011.08927.x

  8. 8.

    Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933-938.

    Not in our library10.1001/archinte.1991.00400050081016

  9. 9.

    Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913′. Arch Intern Med. 1997;157:1665-1670.

    Not in our library10.1001/archinte.1997.00440360079008

  10. 10.

    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.

    Not in our library10.1001/archinte.158.6.585

  11. 11.

    Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657-660.

    Not in our library

  12. 12.

    Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19-25.

    Not in our library10.1016/j.amjmed.2004.01.018

  13. 13.

    Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3:1611-1617.

    Not in our library10.1111/j.1538-7836.2005.01415.x

  14. 14.

    Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2009;21:722-727.

    Not in our library10.1111/j.1525-1497.2006.00458.x

  15. 15.

    Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692-699.

    Not in our library10.1111/j.1538-7836.2007.02450.x

  16. 16.

    Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009;28:401-409.

    Not in our library10.1007/s11239-009-0378-3

  17. 17.

    Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(832):e813-e821.

    Not in our library10.1016/j.amjmed.2013.02.024

  18. 18.

    Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med. 2014;127(829–839):e825.

    Not in our library10.1016/j.amjmed.2014.03.041

  19. 19.

    Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925-1933.

    Not in our library10.1016/s0140-6736(04)16405-2

  20. 20.

    Koton S, Schneider AL, Rosamond WD, et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312:259-268.

    Not in our library10.1001/jama.2014.7692

  21. 21.

    White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128:737-740.

    Not in our library10.7326/0003-4819-128-9-199805010-00006

  22. 22.

    Schneider D, Lilienfeld DE, Im W. The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J Natl Med Assoc. 2006;98:1967-1972.

    Not in our library

  23. 23.

    Zakai NA, McClure LA, Judd SE, et al. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation. 2014;129:1502-1509.

    Not in our library10.1161/circulationaha.113.006472

  24. 24.

    Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg. 2004;91:424-428.

    Not in our library10.1002/bjs.4454

  25. 25.

    Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol. 2000;85:1334-1337.

    Not in our library10.1016/s0002-9149(00)00766-9

  26. 26.

    White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93:298-305.

    Not in our library10.1160/th04-08-0506

  27. 27.

    Hooper WC, Holman RC, Heit JA, Cobb N. Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb Res. 2002;108:273-278.

    Not in our library10.1016/s0049-3848(03)00058-6

  28. 28.

    Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245-1248.

    Not in our library10.1001/archinte.162.11.1245

  29. 29.

    Spencer FA. Personal communication

    Not in our library

  30. 30.

    Heit JA, Sobell JL, Li H, Sommer SS. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. JTH. 2005;3:305-311.

    Not in our library10.1111/j.1538-7836.2004.01117.x

  31. 31.

    Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.

    Not in our library10.7326/0003-4819-125-1-199607010-00001

  32. 32.

    Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768.

    Not in our library10.1001/archinte.160.6.761

  33. 33.

    Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.

    Not in our library10.1001/archinte.160.6.769

  34. 34.

    van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med. 2003;163:1285-1293.

    Not in our library10.1001/archinte.163.11.1285

  35. 35.

    Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. JTH. 2006;4:734-742.

    Not in our library10.1111/j.1538-7836.2006.01795.x

  36. 36.

    Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199-205.

    Not in our library10.3324/haematol.10516

  37. 37.

    Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med. 2008;168:425-430.

    Not in our library10.1001/archinternmed.2007.69

  38. 38.

    Nieto JA, Camara T, Gonzalez-Higueras E, et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:789-796.

    Not in our library

  39. 39.

    White RH, Chan WS, Zhou H, Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost. 2008;100:246-252.

    Not in our library

  40. 40.

    Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet. 2010;376:2032-2039.

    Not in our library10.1016/s0140-6736(10)60962-2

  41. 41.

    Verso M, Agnelli G, Ageno W, et al. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thromb Res. 2012;130:369-373.

    Not in our library10.1016/j.thromres.2012.04.003

  42. 42.

    Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336:393-398.

    Not in our library10.1056/nejm199702063360601

  43. 43.

    Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.

    Not in our library10.1056/nejm199903253401201

  44. 44.

    Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001;345:165-169.

    Not in our library10.1056/nejm200107193450302

  45. 45.

    Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332:1661-1665.

    Not in our library10.1056/nejm199506223322501

  46. 46.

    Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19-25.

    Not in our library10.7326/0003-4819-139-1-200307010-00008

  47. 47.

    Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955-960.

    Not in our library10.7326/0003-4819-137-12-200212170-00008

  48. 48.

    Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wien Klin Wochenschr. 2003;115:471-474.

    Not in our library10.1007/bf03041030

  49. 49.

    Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000;160:3431-3436.

    Not in our library10.1001/archinte.160.22.3431

  50. 50.

    Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 2002;88:407-414.

    Not in our library

  51. 51.

    Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558-2563.

    Not in our library10.1056/nejmoa032959

  52. 52.

    Laczkovics C, Grafenhofer H, Kaider A, et al. Risk of recurrence after a first venous thromboembolic event in young women. Haematologica. 2007;92:1201-1207.

    Not in our library10.3324/haematol.10967

  53. 53.

    Kim TM, Kim JS, Han SW, et al. Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea. Thromb Res. 2009;123:436-443.

    Not in our library10.1016/j.thromres.2008.05.009

  54. 54.

    Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168:1678-1683.

    Not in our library10.1001/archinte.168.15.1678

  55. 55.

    Romualdi E, Squizzato A, Ageno W. Abdominal obesity and the risk of recurrent deep vein thrombosis. Thromb Res. 2007;119:687-690.

    Not in our library10.1016/j.thromres.2006.05.013

  56. 56.

    Garcia-Fuster MJ, Forner MJ, Fernandez C, Gil J, Vaya A, Maldonado L. Long-term prospective study of recurrent venous thromboembolism in patients younger than 50 years. Pathophysiol Haemost Thromb. 2005;34:6-12.

    Not in our library10.1159/000088541

  57. 57.

    Heit JA, Cunningham JM, Petterson TM, Armasu SM, Rider DN, DEA M. Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolism. JTH. 2011;9:1133-1142.

    Not in our library10.1111/j.1538-7836.2011.04272.x

  58. 58.

    Agnelli G, Becattini C, Prandoni P. Recurrent venous thromboembolism in men and women. N Engl J Med. 2004;351:2015-2018.

    Not in our library10.1056/nejm200411043511919

  59. 59.

    Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526.

    Not in our library10.1016/s0140-6736(03)14111-6

  60. 60.

    Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. JTH. 2004;2:2152-2155.

    Not in our library10.1111/j.1538-7836.2004.01050.x

  61. 61.

    McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368:371-378.

    Not in our library10.1016/s0140-6736(06)69110-1

  62. 62.

    Lijfering WM, Veeger NJ, Middeldorp S, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood. 2009;114:2031-2036.

    Not in our library10.1182/blood-2009-04-215418

  63. 63.

    Le Gal G, Kovacs MJ, Carrier M, et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost. 2010;104:498-503.

    Not in our library10.1160/th09-10-0685

  64. 64.

    Christiansen SC, Lijfering WM, Helmerhorst FM, Rosendaal FR, Cannegieter SC. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. JTH. 2010;8:2159-2168.

    Not in our library10.1111/j.1538-7836.2010.03994.x

  65. 65.

    Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ. 2011;342:d813.

    Not in our library10.1136/bmj.d813

  66. 66.

    Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078-3083.

    Not in our library10.1200/jco.2000.18.17.3078

  67. 67.

    Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453-2460.

    Not in our library10.1161/01.cir.103.20.2453

  68. 68.

    Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.

    Not in our library10.1182/blood-2002-01-0108

  69. 69.

    Louzada ML, Majeed H, Dao V, Wells PS. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis. 2011;22:86-91.

    Not in our library10.1097/mbc.0b013e328341f030

  70. 70.

    Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126:448-454.

    Not in our library10.1161/circulationaha.111.051920

  71. 71.

    Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123:3972-3978.

    Not in our library10.1182/blood-2014-01-549733

  72. 72.

    Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170:1710-1716.

    Not in our library10.1001/archinternmed.2010.367

  73. 73.

    Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. JTH. 2010;8:2436-2442.

    Not in our library10.1111/j.1538-7836.2010.04022.x

  74. 74.

    Kovacs MJ, Kahn SR, Wells PS, et al. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. JTH. 2010;8:1926-1932.

    Not in our library10.1111/j.1538-7836.2010.03958.x

  75. 75.

    Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998;104:332-338.

    Not in our library10.1016/s0002-9343(98)00060-6

  76. 76.

    van den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157:2227-2232.

    Not in our library10.1001/archinte.1997.00440400077009

  77. 77.

    Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European prospective cohort on thrombophilia (EPCOT). JTH. 2005;3:459-464.

    Not in our library10.1111/j.1538-7836.2005.01197.x

  78. 78.

    Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger NJ, van der Meer J. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost. 2009;101:93-99.

    Not in our library

  79. 79.

    den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood. 2007;109:139-144.

    Not in our library10.1182/blood-2006-04-014654

  80. 80.

    Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(481–490):W494.

    Not in our library10.7326/0003-4819-149-7-200810070-00008

  81. 81.

    Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153:523-531.

    Not in our library10.7326/0003-4819-153-8-201010190-00009

  82. 82.

    Cosmi B, Legnani C, Tosetto A, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood. 2010;115:481-488.

    Not in our library10.1182/blood-2009-08-237354

  83. 83.

    Palareti G, Cosmi B, Legnani C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014;124:196-203.

    Not in our library10.1182/blood-2014-01-548065

  84. 84.

    Tan M, Mos IC, Klok FA, Huisman MV. Residual venous thrombosis as predictive factor for recurrent venous thromboembolim in patients with proximal deep vein thrombosis: a sytematic review. Br J Haematol. 2011;153:168-178.

    Not in our library10.1111/j.1365-2141.2011.08578.x

  85. 85.

    Le Gal G, Carrier M, Kovacs MJ, et al. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. JTH. 2011;9:1126-1132.

    Not in our library10.1111/j.1538-7836.2011.04240.x

  86. 86.

    Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29:298-310.

    Not in our library10.1161/atvbaha.108.182428

  87. 87.

    Cushman M, Glynn RJ, Goldhaber SZ, et al. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. JTH. 2006;4:2199-2203.

    Not in our library10.1111/j.1538-7836.2006.02140.x

  88. 88.

    White RH, Murin S, Wun T, Danielsen B. Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. JTH. 2010;8:987-997.

    Not in our library10.1111/j.1538-7836.2010.03798.x

  89. 89.

    Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med. 2001;110:515-519.

    Not in our library10.1016/s0002-9343(01)00661-1

  90. 90.

    Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch of Internal Medicine. 2004;164:92-96.

    Not in our library10.1001/archinte.164.1.92

  91. 91.

    Jimenez D, Diaz G, Marin E, Vidal R, Sueiro A, Yusen RD. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost. 2006;95:562-566.

    Not in our library10.1160/th05-10-0677

  92. 92.

    Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036.

    Not in our library10.1136/bmj.d3036

  93. 93.

    Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179:417-426.

    Not in our library10.1503/cmaj.080493

  94. 94.

    Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630-1636.

    Not in our library10.1161/circulationaha.109.925214

  95. 95.

    Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). JTH. 2012;10:1019-1025.

    Not in our library10.1111/j.1538-7836.2012.04735.x

  96. 96.

    Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost. 2012;108:1061-1064.

    Not in our library10.1160/th12-05-0353

  97. 97.

    Poli D, Palareti G. Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med. 2013;19:407-412.

    Not in our library10.1097/mcp.0b013e328363ed7c

  98. 98.

    den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. JTH. 2013;11:998-1000.

    Not in our library10.1111/jth.12192

  99. 99.

    Heit JA. Estimating the incidence of symptomatic postoperative venous thromboembolism: the importance of perspective. JAMA. 2012;307:306-307.

    Not in our library10.1001/jama.2011.2013

  100. 100.

    Yusuf H, Tsai J, Atrash HK, Boulet LP, Grosse SD. Venous thromboembolism in adult hospitalizations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep. 2012;61:401-404.

    Not in our library

  101. 101.

    Cohoon KP, Leibson CL, Ransom JE, et al. Costs of venous thromboembolism associated with hospitalization for medical illness. Am J Manag Care. 2015;21(4):e255-e263.

    Not in our library

  102. 102.

    Cohoon KP, Leibson CL, Ransom JE, et al. Direct medical costs attributable to venous thromboembolism among persons hospitalized for major operation: a population-based longitudinal study. Surgery. 2015;157:423-431.

    Not in our library10.1016/j.surg.2014.10.005

  103. 103.

    Cohoon KP, Leibson CL, Ransom JE, et al (2015) Direct medical costs attributalbe to cancer-associated venous thromboembolism: a population-based longitudinal study. J Oncol Pract

    Not in our library10.1016/j.amjmed.2016.02.030

  104. 104.

    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159:445-453.

    Not in our library10.1001/archinte.159.5.445

  105. 105.

    Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389.

    Not in our library10.1016/s0140-6736(98)07534-5

  106. 106.

    Janata K, Holzer M, Domanovits H, et al. Mortality of patients with pulmonary embolism. Wien Klin Wochenschr. 2002;114:766-772.

    Not in our library

  107. 107.

    Andresen MS, Sandven I, Brunborg C, et al. Mortality and recurrence after treatment of VTE: long term follow-up of patients with good life-expectancy. Thromb Res. 2011;127:540-546.

    Not in our library10.1016/j.thromres.2011.02.017

  108. 108.

    Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010;363:266-274.

    Not in our library10.1056/nejmra0907731

  109. 109.

    Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96:882-888.

    Not in our library10.1161/01.cir.96.3.882

  110. 110.

    Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med. 2003;163:1711-1717.

    Not in our library10.1001/archinte.163.14.1711

  111. 111.

    Tsai J, Grosse SD, Grant AM, Hooper WC, Atrash HK. Trends in in-hospital deaths among hospitalizations with pulmonary embolism. Arch Intern Med. 2012;172:960-961.

    Not in our library10.1001/archinternmed.2012.198

  112. 112.

    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.

    Not in our library10.1001/archinte.160.6.809

  113. 113.

    Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 2003;101:1243-1248.

    Not in our library10.1182/blood-2002-05-1416

  114. 114.

    Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075-1079.

    Not in our library10.1016/s0140-6736(06)68474-2

  115. 115.

    Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583.

    Not in our library10.1136/bmj.b4583

  116. 116.

    Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169:610-615.

    Not in our library10.1001/archinternmed.2008.589

  117. 117.

    Barsoum MK, Heit JA, Ashrani AA, Leibson CL, Petterson TM, Bailey KR. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb Res. 2010;126:373-378.

    Not in our library10.1016/j.thromres.2010.08.010

  118. 118.

    Roach RE, Lijfering WM, Flinterman LE, Rosendaal FR, Cannegieter SC. Increased risk of CVD after VT is determined by common etiologic factors. Blood. 2013;121:4948-4954.

    Not in our library10.1182/blood-2013-01-479238

  119. 119.

    Heit JA, Melton LJ, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001;76:1102-1110.

    Not in our library10.4065/76.11.1102

  120. 120.

    Noboa S, Mottier D, Oger E. Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study. JTH. 2006;4:2720-2722.

    Not in our library10.1111/j.1538-7836.2006.02196.x

  121. 121.

    Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160:3415-3420.

    Not in our library10.1001/archinte.160.22.3415

  122. 122.

    Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S-453S.

    Not in our library10.1378/chest.08-0656

  123. 123.

    Sweetland S, Parkin L, Balkwill A, Green J, Reeves G, Beral V. Smoking, surgery, and venous thromboembolism risk in women: United Kingdom cohort study. Circulation. 2013;127:1276-1282.

    Not in our library10.1161/circulationaha.113.001428

  124. 124.

    White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90:446-455.

    Not in our library10.1160/th03-03-0152

  125. 125.

    Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg. 2004;74:1082-1097.

    Not in our library10.1111/j.1445-1433.2004.03258.x

  126. 126.

    Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93:259-262.

    Not in our library10.1016/j.amjcard.2003.09.057

  127. 127.

    Anderson FA, Hirsh J, White K, Fitzgerald RH. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest. 2003;124:349S-356S.

    Not in our library10.1378/chest.124.6_suppl.349s

  128. 128.

    White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000;343:1758-1764.

    Not in our library10.1056/nejm200012143432403

  129. 129.

    Parkin L, Sweetland S, Balkwill A, Green J, Reeves G, Beral V. Body mass index, surgery, and risk of venous thromboembolism in middle-aged women: a cohort study. Circulation. 2012;125:1897-1904.

    Not in our library10.1161/circulationaha.111.063354

  130. 130.

    Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology. 2003;99:552-560.

    Not in our library10.1097/00000542-200309000-00009

  131. 131.

    Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. JTH. 2004;2:2156-2161.

    Not in our library10.1111/j.1538-7836.2004.00991.x

  132. 132.

    Chopard P, Spirk D, Bounameaux H. Identifying acutely ill medical patients requiring thromboprophylaxis. JTH. 2006;4:915-916.

    Not in our library10.1111/j.1538-7836.2006.01818.x

  133. 133.

    Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the padua prediction score. JTH. 2010;8:2450-2457.

    Not in our library10.1111/j.1538-7836.2010.04044.x

  134. 134.

    Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP. Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med. 2011;6:202-209.

    Not in our library10.1002/jhm.888

  135. 135.

    Spyropoulos AC, Anderson FA, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140:706-714.

    Not in our library10.1378/chest.10-1944

  136. 136.

    Woller SC, Stevens SM, Jones JP, et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med. 2011;124(947–954):e942.

    Not in our library10.1016/j.amjmed.2011.06.004

  137. 137.

    Zakai NA, Callas PW, Repp AB, Cushman M. Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. JTH. 2013;11:634-641.

    Not in our library10.1111/jth.12147

  138. 138.

    Samama MM, Combe S, Conard J, Horellou MH. Risk assessment models for thromboprophylaxis of medical patients. Thromb Res. 2012;129:127-132.

    Not in our library10.1016/j.thromres.2011.09.025

  139. 139.

    Rothberg MB. Venous thromboembolism prophylaxis for medical patients: who needs it? JAMA Intern Med. 2014;174:1585-1586.

    Not in our library10.1001/jamainternmed.2014.3357

  140. 140.

    Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-464.

    Not in our library10.1001/archinte.166.4.458

  141. 141.

    Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. JTH. 2006;4:529-535.

    Not in our library10.1111/j.1538-7836.2006.01804.x

  142. 142.

    Kucuk O, Kwaan HC, Gunnar W, Vazquez RM. Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer. 1985;55:702-706.

    Not in our library10.1002/1097-0142(19850215)55:4<702::aid-cncr2820550405>3.0.co;2-n

  143. 143.

    Liebman HA, Wada JK, Patch MJ, McGehee W. Depression of functional and antigenic plasma antithrombin III (AT-III) due to therapy with L-asparaginase. Cancer. 1982;50:451-456.

    Not in our library10.1002/1097-0142(19820801)50:3<451::aid-cncr2820500312>3.0.co;2-4

  144. 144.

    Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.

    Not in our library10.1182/blood.v98.5.1614

  145. 145.

    Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354:2079-2080.

    Not in our library10.1056/nejmc053530

  146. 146.

    Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45:608-612.

    Not in our library10.1046/j.1365-2125.1998.00733.x

  147. 147.

    Tafur AJ, Kalsi H, Wysokinski WE, et al. The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clin Proc. 2011;86:25-30.

    Not in our library10.4065/mcp.2010.0339

  148. 148.

    Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149:323-333.

    Not in our library10.7326/0003-4819-149-5-200809020-00007

  149. 149.

    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907.

    Not in our library10.1182/blood-2007-10-116327

  150. 150.

    Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377-5382.

    Not in our library10.1182/blood-2010-02-270116

  151. 151.

    Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA. 2001;286:700-707.

    Not in our library10.1001/jama.286.6.700

  152. 152.

    Decousus H, Quere I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med. 2010;152:218-224.

    Not in our library10.7326/0003-4819-152-4-201002160-00006

  153. 153.

    Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med. 1983;74:1023-1028.

    Not in our library10.1016/0002-9343(83)90805-7

  154. 154.

    Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med. 1994;154:164-168.

    Not in our library10.1001/archinte.1994.00420020066008

  155. 155.

    Dalen JE. Economy class syndrome: too much flying or too much sitting? Arch Intern Med. 2003;163:2674-2676.

    Not in our library10.1001/archinte.163.2.239

  156. 156.

    Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Buller HR, Rosendaal FR. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med. 2007;4:e290.

    Not in our library10.1371/journal.pmed.0040290

  157. 157.

    Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med. 2009;151:180-190.

    Not in our library10.7326/0003-4819-151-3-200908040-00129

  158. 158.

    Watson HG, Baglin TP. Guidelines on travel-related venous thrombosis. Br J Haematol. 2011;152:31-34.

    Not in our library10.1111/j.1365-2141.2010.08408.x

  159. 159.

    Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med. 2001;161:1405-1410.

    Not in our library10.1001/archinte.161.11.1405

  160. 160.

    Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol. 2004;18:477-482.

    Not in our library10.1111/j.1472-8206.2004.00252.x

  161. 161.

    Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-1861.

    Not in our library10.1056/nejmoa0900241

  162. 162.

    Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970-1975.

    Not in our library10.1161/01.atv.0000143134.87051.46

  163. 163.

    Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435-1441.

    Not in our library10.1056/nejmoa022157

  164. 164.

    Marcucci R, Liotta AA, Cellai AP, et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med. 2003;115:601-605.

    Not in our library10.1016/j.amjmed.2003.06.005

  165. 165.

    Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182-1189.

    Not in our library10.1001/archinte.162.10.1182

  166. 166.

    Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370:1773-1779.

    Not in our library10.1016/s0140-6736(07)61745-0

  167. 167.

    Zoller B, Li X, Sundquist J, Sundquist K. Venous thromboembolism does not share strong familial susceptibility with coronary heart disease: a nationwide family study in Sweden. Eur Heart J. 2011;32:2800-2805.

    Not in our library10.1093/eurheartj/ehr223

  168. 168.

    Barsoum MK, Cohoon KP, Roger VL, et al. Are myocardial infarction and venous thromboembolism associated? Population-based case-control and cohort studies. Thromb Res. 2014;134:593-598.

    Not in our library10.1016/j.thromres.2014.06.033

  169. 169.

    Folsom AR, Chamberlain A. Lipoprotein(a) and venous thromboembolism. Am J Med. 2008;121:e17.

    Not in our library10.1016/j.amjmed.2007.10.008

  170. 170.

    Chamberlain AM, Folsom AR, Heckbert SR, Rosamond WD, Cushman M. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). Blood. 2008;112:2675-2680.

    Not in our library10.1182/blood-2008-05-157412

  171. 171.

    Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med. 1998;128:467-477.

    Not in our library10.7326/0003-4819-128-6-199803150-00008

  172. 172.

    Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82:610-619.

    Not in our library

  173. 173.

    Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965-1976.

    Not in our library10.1001/archinte.164.18.1965

  174. 174.

    Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-696.

    Not in our library10.7326/0003-4819-132-9-200005020-00002

  175. 175.

    Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA. 1997;278:477.

    Not in our library10.1001/jama.1997.03550060053030

  176. 176.

    Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697-706.

    Not in our library10.7326/0003-4819-143-10-200511150-00006

  177. 177.

    Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008;99:338-342.

    Not in our library

  178. 178.

    van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010;30:2297-2300.

    Not in our library10.1161/atvbaha.110.211482

  179. 179.

    Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292:1581-1587.

    Not in our library10.1001/jama.292.13.1581

  180. 180.

    Scarabin P-Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428-432.

    Not in our library10.1016/s0140-6736(03)14066-4

  181. 181.

    James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. 2009;29:326-331.

    Not in our library10.1161/atvbaha.109.184127

  182. 182.

    Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol. 2001;184:104-110.

    Not in our library10.1067/mob.2001.107919

  183. 183.

    Roach RE, Lijfering WM, van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR, Cannegieter SC. The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood. 2013;122:4264-4269.

    Not in our library10.1182/blood-2013-07-518159

  184. 184.

    Ludvigsson JF, Welander A, Lassila R, Ekbom A, Montgomery SM. Risk of thromboembolism in 14,000 individuals with coeliac disease. Br J Haematol. 2007;139:121-127.

    Not in our library10.1111/j.1365-2141.2007.06766.x

  185. 185.

    Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest. 2009;135:1651-1664.

    Not in our library10.1378/chest.08-2830

  186. 186.

    Tsai AW, Cushman M, Tsai MY, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol. 2003;72:192-200.

    Not in our library10.1002/ajh.10287

  187. 187.

    Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. JTH. 2005;3:292-299.

    Not in our library10.1111/j.1538-7836.2005.01141.x

  188. 188.

    van Zaane B, Squizzato A, Huijgen R, et al. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood. 2010;115:4344-4349.

    Not in our library10.1182/blood-2009-11-253724

  189. 189.

    Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011;152:360-362.

    Not in our library10.1111/j.1365-2141.2010.08418.x

  190. 190.

    Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121:4782-4790.

    Not in our library10.1182/blood-2012-12-467068

  191. 191.

    Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657-663.

    Not in our library10.1016/s0140-6736(09)61963-2

  192. 192.

    Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113:5617-5623.

    Not in our library10.1182/blood-2008-12-196014

  193. 193.

    Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115:778-782.

    Not in our library10.1182/blood-2009-08-238956

  194. 194.

    Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant. 2010;25:3296-3301.

    Not in our library10.1093/ndt/gfq179

  195. 195.

    Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med. 2008;121:226-230.

    Not in our library10.1016/j.amjmed.2007.08.042

  196. 196.

    Brodsky RA (2008) Paroxysmal nocturnal hemoglobinuria: stem cells and clonality. Hematology. Am Soc Hematol Educ Program pp 111–115

    Not in our library10.1182/asheducation-2008.1.111

  197. 197.

    Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012;64:53-61.

    Not in our library10.1002/art.33322

  198. 198.

    Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308:1350-1356.

    Not in our library10.1001/2012.jama.11741

  199. 199.

    Arnulf I, Merino-Andreu M, Perrier A, Birolleau S, Similowski T, Derenne JP. Obstructive sleep apnea and venous thromboembolism. JAMA. 2002;287:2655-2656.

    Not in our library10.1001/jama.287.20.2655

  200. 200.

    Peng YH, Liao WC, Chung WS, et al. Association between obstructive sleep apnea and deep vein thrombosis/pulmonary embolism: a population-based retrospective cohort study. Thromb Res. 2014;134:340-345.

    Not in our library10.1016/j.thromres.2014.06.009

  201. 201.

    Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007;110:908-912.

    Not in our library10.1182/blood-2006-11-057604

  202. 202.

    Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142:620-626.

    Not in our library10.7326/0003-4819-142-8-200505030-00011

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.